摘要
目的分析阿托伐他汀与曲美他嗪联合治疗对冠心病患者心功能、炎性因子和内皮功能的影响。方法选取本院2018年6月-2019年6月收治的64例冠心病患者作为研究对象,随机分为两组,其中32例采用曲美他嗪治疗,记为对照组,32例采用阿托伐他汀联合曲美他嗪治疗,记为观察组,对比两组患者治疗后的心功能、炎性因子和内皮功能。结果治疗后,观察组的心功能指标为:左心室射血分数(37.55±5.27)%,左心室舒张末期内径(46.52±4.28)mm,左室后壁厚度(8.61±0.13)mm,优于于对照组的左心室射血分数(44.62±6.04)%,左心室舒张末期内径(55.21±5.07)mm,左室后壁厚度(10.86±0.94)mm(P<0.05);观察组的炎性因子指标超敏C反应蛋白(2.37±0.63)ng/L,基质金属蛋白酶(32.04±10.31)ng/L,肿瘤坏死因子(95.17±21.74)ng/L,低于对照组的超敏C反应蛋白(4.19±0.87)ng/L,基质金属蛋白酶(40.45±11.28)ng/L,肿瘤坏死因子(157.33±32.51)ng/L(P<0.05);观察组的内皮功能为外周血循环内皮微颗粒(847.68±12.57)×10^6/L,一氧化氮(389.37±5.16)μg/mL,血管内皮素-1(63.71±2.31)μg/mL,优于对照组的外周血循环内皮微颗粒(1005.68±11.44)×10^6/L,一氧化氮(317.54±5.05)μg/mL,血管内皮素-1(79.68±2.55)μg/mL(P<0.05)。结论相比单纯采用曲美他嗪治疗,对冠心病患者采用阿托伐他汀与曲美他嗪联合治疗,更能有效改善患者的心功能和血管内皮功能,减少炎性因子,疗效确切,值得推广。
Objective To investigate the effect of atorvastatin combined with trimetazidine on cardiac function,inflammatory factors and endothelial function in patients with coronary heart disease.Methods Sixty-four patients with coronary heart disease admitted to a hospital from June 2018 to June 2019 were enrolled in this study,and they were randomly divided into a control group and a trial group,with 32 cases in each group.The patients in the control group were treated with trimetazidine and the patients in the trial group were treated with the combination of atorvastatin and trimetazidine.The cardiac function,inflammatory factors and endothelial function after the treatment were investigated,analyzed and compared between the two groups.Results After the treatment,in the trial group,the cardiac function indexes:left ventricular ejection fraction(37.55±5.27) %,left ventricular end diastolic diameter(46.52±4.28) mm,and left ventricular posterior wall thickness(8.61±0.13) mm,were superior to those in the control group [the left ventricular ejection fraction(44.62±6.04) %,left ventricular end-diastolic diameter(55.21±5.07) mm,and left ventricular posterior wall thickness(10.86±0.94) mm](P <0.05).In the trial group,the inflammation factor hypersensitive C-reactive protein [(2.37±0.63) ng/L],matrix metalloproteinase[(32.04±10.31) ng/L],and tumor necrosis factor [(95.17±21.74) ng/L] were lower than those in the control group [the inflammation factor hypersensitive C-reactive protein(4.19±0.87) ng/L,matrix metalloproteinase(40.45±11.28) ng/L,and tumor necrosis factor(157.33±32.51) ng/L](P <0.05).In the trial group,the endothelial functions:peripheral blood circulation endothelial microparticles [(847.68±12.57)*10^6/L],nitric oxide [(389.37±5.16) μg/mL],and vascular endothelin-1 [(63.71±2.31) μg/mL] were superior to those in the control group[peripheral blood circulating endothelial microparticles(1005.68±11.44)*10^6/L],nitric oxide [(317.54±5.05) μg/mL],and vascular endothelin-1 [(79.68±2.55) μg/mL](P <0.05
作者
韩杰
纠萌
HAN Jie;JIU meng(Cardiovascular ward 5,Henan Chest Hospital,Zhengzhou 450000,Henan,China)
出处
《中国校医》
2020年第7期498-499,507,共3页
Chinese Journal of School Doctor
关键词
冠心病
曲美他嗪
阿托伐他汀
血管内皮功能
心功能
炎性因子
coronary heart disease
trimetazidine
atorvastatin
vascular endothelial function
cardiac function
inflammatory factor
